BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Suzhou Sanegene Bio readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Suzhou Sanegene Bio's drugs run\,
  from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07352969-533@assetmemo.bio
DTSTAMP:20261121T005937Z
DTSTART;VALUE=DATE:20290327
DTEND;VALUE=DATE:20290328
SUMMARY:IBI3016: Phase 2 readout est. (NCT07352969)
DESCRIPTION:IBI3016\, phase 2\, Hypertension.\nStudy: A Dose Finding Study 
 of IBI3016 in Mild to Moderate Hypertensive Patients\nEstimated primary co
 mpletion: 27 March 2029. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/ibi3016#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07352969
URL:https://assetmemo.bio/drug/ibi3016#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
